Literature DB >> 19861161

c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment.

Jae J Song1, Joo-Hang Kim, Bo K Sun, Marco A Alcala, David L Bartlett, Yong J Lee.   

Abstract

We have previously observed that TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) induces acquired TRAIL resistance by increasing Akt phosphorylation and Bcl-xL expression. In this study, we report that Src, c-Cbl, and PI3K are involved in the phosphorylation of Akt during TRAIL treatment. Data from immunoprecipitation and immunoblotting assay reveal that Src interacts with c-Cbl and PI3K. Data from immune complex kinase assay demonstrate that Src can directly phosphorylate c-Cbl and PI3K p85 subunit protein. Data from gene knockdown experiments with an RNA interference (RNAi) technique show that c-Cbl is involved in the interaction between Src and PI3K p85 during TRAIL treatment, playing an important role in TRAIL-induced Akt phosphorylation. Taken together, c-Cbl may act as a mediator to regulate the Src-PI3K-Akt signal transduction pathway during TRAIL treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19861161      PMCID: PMC2965849          DOI: 10.1016/j.cellsig.2009.10.007

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  34 in total

Review 1.  New roles for Src kinases in control of cell survival and angiogenesis.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-02-04       Impact factor: 41.582

2.  Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells.

Authors:  D Fang; H Y Wang; N Fang; Y Altman; C Elly; Y C Liu
Journal:  J Biol Chem       Date:  2000-11-21       Impact factor: 5.157

Review 3.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

4.  Src-catalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins.

Authors:  M Yokouchi; T Kondo; A Sanjay; A Houghton; A Yoshimura; S Komiya; H Zhang; R Baron
Journal:  J Biol Chem       Date:  2001-07-11       Impact factor: 5.157

Review 5.  On the TRAIL to apoptosis.

Authors:  Tudor M Baetu; John Hiscott
Journal:  Cytokine Growth Factor Rev       Date:  2002-06       Impact factor: 7.638

6.  The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase.

Authors:  Y Lin; A Devin; A Cook; M M Keane; M Kelliher; S Lipkowitz; Z G Liu
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

7.  Inhibition of Src family kinases blocks epidermal growth factor (EGF)-induced activation of Akt, phosphorylation of c-Cbl, and ubiquitination of the EGF receptor.

Authors:  C Kenneth Kassenbrock; Seija Hunter; Pamela Garl; Gary L Johnson; Steven M Anderson
Journal:  J Biol Chem       Date:  2002-05-06       Impact factor: 5.157

8.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt.

Authors:  Jacques Morel; Rachel Audo; Michael Hahne; Bernard Combe
Journal:  J Biol Chem       Date:  2005-01-31       Impact factor: 5.157

9.  PI-3K/Akt and NF-kappaB/IkappaBalpha pathways are activated in Jurkat T cells in response to TRAIL treatment.

Authors:  Giorgio Zauli; Silvia Sancilio; Amelia Cataldi; Nadia Sabatini; Domenico Bosco; Roberta Di Pietro
Journal:  J Cell Physiol       Date:  2005-03       Impact factor: 6.384

10.  Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo.

Authors:  R G Jones; M Parsons; M Bonnard; V S Chan; W C Yeh; J R Woodgett; P S Ohashi
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

View more
  20 in total

1.  OX40 complexes with phosphoinositide 3-kinase and protein kinase B (PKB) to augment TCR-dependent PKB signaling.

Authors:  Takanori So; Heonsik Choi; Michael Croft
Journal:  J Immunol       Date:  2011-02-02       Impact factor: 5.422

2.  CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.

Authors:  Paula Aranaz; Cristina Hurtado; Ignacio Erquiaga; Itziar Miguéliz; Cristina Ormazábal; Ion Cristobal; Marina García-Delgado; Francisco Javier Novo; José Luis Vizmanos
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 3.  Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.

Authors:  Xiaoyun Dai; Jingwen Zhang; Frank Arfuso; Arunachalam Chinnathambi; M E Zayed; Sulaiman Ali Alharbi; Alan Prem Kumar; Kwang Seok Ahn; Gautam Sethi
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-07

Review 4.  Surviving apoptosis: life-death signaling in single cells.

Authors:  Deborah A Flusberg; Peter K Sorger
Journal:  Trends Cell Biol       Date:  2015-04-25       Impact factor: 20.808

5.  Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype.

Authors:  Simone Martinelli; Alessandro De Luca; Emilia Stellacci; Cesare Rossi; Saula Checquolo; Francesca Lepri; Viviana Caputo; Marianna Silvano; Francesco Buscherini; Federica Consoli; Grazia Ferrara; Maria C Digilio; Maria L Cavaliere; Johanna M van Hagen; Giuseppe Zampino; Ineke van der Burgt; Giovanni B Ferrero; Laura Mazzanti; Isabella Screpanti; Helger G Yntema; Willy M Nillesen; Ravi Savarirayan; Martin Zenker; Bruno Dallapiccola; Bruce D Gelb; Marco Tartaglia
Journal:  Am J Hum Genet       Date:  2010-07-08       Impact factor: 11.025

6.  MEKK1/MEKK4 are responsible for TRAIL-induced JNK/p38 phosphorylation.

Authors:  Bo K Sun; Joo-Hang Kim; Hoan N Nguyen; Seeun Oh; So Y Kim; Sujin Choi; Hye J Choi; Yong J Lee; Jae J Song
Journal:  Oncol Rep       Date:  2010-12-07       Impact factor: 3.906

7.  Molecular and genetic properties of tumors associated with local immune cytolytic activity.

Authors:  Michael S Rooney; Sachet A Shukla; Catherine J Wu; Gad Getz; Nir Hacohen
Journal:  Cell       Date:  2015-01-15       Impact factor: 41.582

8.  Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells.

Authors:  Jing Xu; Jun-Ying Zhou; Wei-Zen Wei; Gen Sheng Wu
Journal:  PLoS One       Date:  2010-04-19       Impact factor: 3.240

9.  mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis.

Authors:  Liqun Zhao; Ping Yue; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Res       Date:  2013-01-14       Impact factor: 12.701

10.  Regulation of the Src-PP2A interaction in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.

Authors:  Jing Xu; Zhengfan Xu; Jun-Ying Zhou; Zhengping Zhuang; Enhua Wang; Julie Boerner; Gen Sheng Wu
Journal:  J Biol Chem       Date:  2013-10-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.